
Stuart Hood, Consultant Cardiologist
Irene
Robertson
Cardiology Department, Royal Alexandra Hospital, Paisley, PA2 9PN
SMJ 2004 49(3): 90-92
Abstract
Background
and Aims
Erectile
dysfunction (ED) is a common condition, which negatively affects quality of
life, and shares similar risk factors with Coronary Heart Disease (CHD). Studies
from the pre – sildenafil era confirm a higher risk of ED in patients with
cardiovascular disease. The high profile and success of sildenafil therapy has
made it easier for some men to discuss erectile difficulties with healthcare
professionals. Our aim therefore was to estimate the prevalence of ED in our
cardiac rehabilitation patients
Methods
and Results
We
surveyed 150 random male cardiac rehabilitation patients using the International
Index of Erectile Function (IIEF) questionnaire. 61% of all respondents had
erectile difficulties, rising to 75% in the over 55 age group. 48% of
respondents indicated their wish to discuss erectile problems with the
healthcare team.
Conclusion.
ED
and CHD commonly co-exist. A large
proportion of our respondents wished further discussion of erectile
insufficiency. We recommend that cardiac rehabilitation programmes should adopt
a proactive approach to detection and treatment of ED
Key
words: Erectile dysfunction; Cardiac rehabilitation; Coronary Heart Disease
Background
and aims
Erectile
dysfunction (ED) is a common condition. Historical data suggests10% of men in
the general population and 44% of patients with previous myocardial infarction
(MI) may suffer from ED.1,2 This
data however pre dates the availability of successful oral therapy for ED. The
development of sildenafil raised public awareness of ED encouraging some men to
voice their problems. It is possible therefore that these older studies have
underestimated the prevalence of ED and that a significant unmet health need
persists in patients with coronary artery disease. ED negatively influences
quality of life in both patient and partner3 and in one study was
implicated in 20% of relationship breakdowns.4 Despite this, patients
and doctors remain generally reluctant to discuss sexual dysfunction even though
treatment of ED can improve quality of life in both patient and partner.5
Anecdotally, very few patients in our cardiac rehabilitation clinic volunteer
symptoms of ED suggesting many patients may be suffering in silence. Given that
CHD and ED share common risk factors, cardiac rehabilitation programmes are
ideally placed to enquire about symptoms of ED and to initiate treatment. We
undertook this survey to estimate the prevalence of ED in our male CHD subjects.
Methods
and Results
The
International Index of Erectile Function (IIEF) questionnaire (see table
I) was issued to 150 random male participants in our cardiac rehabilitation
programme. Entry into the programme is offered to patients attending our
hospital with a confirmed diagnosis of CHD and is not restricted to those who
have suffered a previous MI or undergone a revascularisation procedure. The IIEF
questionnaire consists of five questions concerning erectile function, orgasmic
function, sexual desire, intercourse satisfaction and overall satisfaction.6
For each question there are several possible answers and subjects circle
the response which best describes their situation. The options are assigned a
score of 0-5 (maximum score 25). A total score of 21 or less indicates potential
erectile dysfunction.
Seventy-five
of 150 (50%) questionnaires were returned, of which 70 (47%) were fully
completed. 43 patients (61%) had IIEF scores of 21 or less indicating possible
erectile dysfunction. IIEF scores <21 were more common in older
patients, occurring in 11 (39%) of patients younger than 55 and in 32 (76%)
patients older than 55. Thirty-six (48%) of respondents wished further
discussion of erectile difficulties. Of those who wished to discuss erectile
issues, 27 patients (75%) had IIEF scores <21. Of patients who
expressed a preference, 16 (31%) felt most comfortable discussing erectile
problems with their hospital cardiologist, 19 (37%) with their GP and 8 (16%)
with cardiac rehabilitation nurses.
Conclusion
We
identified a higher than previously reported prevalence of erectile dysfunction
in male patients with coronary heart disease. This is not unexpected as ED and
cardiovascular disease have similar risk factors. Recent evidence suggests that
endothelial dysfunction is the common denominator in both conditions.7
Of course there are limitations of our small survey, not least a 50% response
rate. Nonetheless, the majority of respondents had erectile problems and a large
number of them indicated a wish to discuss these issues implying a significant,
unmet health need. Cardiac rehabilitation programmes are ideally placed to
identify and treat ED. At present however, few patients in our cardiac
rehabilitation programme seek treatment for ED. Until recently, therapeutic
options for ED were limited and unacceptable to many individuals. Newer, oral
phosphodiesterase treatment is, however, convenient, effective and safe in low
risk cardiac patients. Initial concern over the safety of these drugs has
largely been unfounded but guidelines for risk stratification and management of
ED in cardiovascular patients have been published.8 A proactive
approach, aiming to identify and treat ED in cardiovascular patients, is
recommended.
Conflict of interest: SH has received honoraria for speaking and acting as an advisor for many pharmaceutical companies including Pfizer. Both SH and IR have received assistance with travel costs from Pfizer.
References
Feldman HA,
Goldstein I, Hatzichristou DG et al. impotence and its medical and
psychosocial correlates: results of the Massachusetts Male Ageing Study. J
Urol 1994;151:54-61
Wabrek AJ,
Burchell RC. Male sexual dysfunction associated with coronary heart disease.
Arch Sex Behav 1980;9:69-75.
Dunn KM, Croft
PR, Hackett GI. Association of sexual problems with social, psychological
and physical problems in men and women: a cross sectional population survey.
J Epidemiol Community Health
1998;52:10-14
Impotence
Association Survey. Taylor Nelson AGB Healthcare, 1997
Quirk F, Guiliano F, Pena B et al. Effect of sildanefil on quality-of-life parameters in men with broad
spectrum erectile dysfunction. J Urol
1998;159(suppl 5):260.
Rosen RC, Riley
A, Wagner G et al. The international index of erectile function (IIEF): a
multidimensional scale for assessment of erectile dysfunction. Urology
1997;49(6):822-30.
DeBusk R, Drory
Y, Goldstein I et al. Management of sexual dysfunction in patients with
cardiovascular disease: recommendations of the Princeton Consensus Panel. Am
J Cardiol 2000;86:175-81.